SURVIVAL RESULTS OF PATIENTS WITH HIGH-GRADE AND ADVANCED-STAGE ENDOMETRIAL CANCER

Purpose: To evaluate the overall survival and disease-free survival in patients with advanced-stage(FIGO III-IV) and high-grade endometrium cancer Patients and Methods: Patients with operated due to endometrial cancer between 2003-2014 and detected FIGO-stage III-IV serous, clearcell, carcinosarcoma, mixed, grade 3 endometrioid, and undifferentiated histological types according to postoperative pathology report were selected for the study. Overall survival and disease-free survival times were calculated by Kaplan-Meier survival analysis for each histologic type. Results: A total of 85 patients with a median-age of 65(37-86) were included in the study. Of them, 56(65.9%) were stage-III and 29(34.1%) were stage-IV. The most common histological-type was carcinosarcoma(25.9%, n=22) followed by mixed(22.4%,n=19), serous(17.6%,n=18), grade 3 endometrioid(17.6% cell (8.2%,n=7) and undifferentiated(4.7%,n=4). During a mean follow-up of 37.1 months(1-148), 63 patients(74.1%) had recurrence and 60 patients(70.6%) died. The overall survival rate was 29.4%. The highest survival rates were mixed type and grade 3 endometrioid types(42.1% and 40%) followed by serous(33.3%) and clear-cell(28.6%) and carcinosarcoma(13.6%) and no survival in undifferentiated type. Median disease-free survival and overall survival were 24 and 49 months for serous type, 28 and 34 months for grade 3 endometrioid type, 15 and 27 months for mixed type, 9 and 18 months for clear cell, 10 and 21 months for carcinosarcoma, 3 and 4 months for the undifferentiated type Conclusion: The median disease-free and overall survival of patients were 12 and 28 months, respectively, according to the data of this study. 74.1% of the patients relapse. The worst prognosis is with undifferentiated types. The prognosis for Grade-3 endometrioid and mixedtypes seems to be relatively better